NEW YORK (GenomeWeb) – Belgian molecular diagnostics developer MDxHealth announced today that its ConfirmMDx prostate cancer test has been included as an in-network benefit under the California Medical Assistance Program (Medi-Cal).

Medi-Cal is California's state-run Medicaid program and has approximately 12 million enrollees. With the inclusion of ConfirmMDx in the program, MDxHealth said it will seek access to the test through other US Medicaid programs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.